{"changes":[],"country":"FI","description":"TILT Biotherapeutics develops oncolytic immunotherapies using engineered viruses delivered intravenously to make cold tumors responsive to the immune system. It targets solid-tumor patients who have not responded to existing immunotherapies. Its lead virus is armed with two cytokines, TNF and IL-2, unlike single-payload approaches.","domain":"tiltbio.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":[],"lat":60.16662,"lng":24.943541,"location":"Helsinki, Finland","name":"Tilt Biotherapeutics","rounds":[{"amountQuarantined":false,"amountUsd":2700000,"currency":"EUR","date":"2024-09-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"tiltbio-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"tiltbio.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://tiltbio.com"},{"fact":"description","publisher":"tiltbio.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://tiltbio.com"}],"stage":null,"techStack":["Nginx","PHP","Typekit","Adobe Fonts","jQuery CDN","WordPress","MySQL","jquery 3.1.1"],"totalRaisedUsd":2700000,"updatedAt":"2026-05-08"}